COMPANY PROFILE

PeproMene Bio

Explore full profile

Virtual, privately funded biotech company

Irvine, United StatesFounded 2017Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About PeproMene Bio

PeproMene Bio, Inc. is a clinical stage biotech company based in Irvine, California, focused on developing novel therapies for cancers and immune disorders. The company's flagship program, BAFF R CAR T therapy, leverages a unique antibody targeting the B cell Activating Factor Receptor (BAFF R), discovered by Dr. Larry's team at MD Anderson Cancer Center and City of Hope National Medical Center. This receptor plays a crucial role in B lymphocyte differentiation and mature B cell survival, making it a promising target for treating B cell malignancies such as Non-Hodgkin Lymphoma (B NHL) and Acute Lymphoblastic Leukemia (B ALL). PeproMene Bio operates in the biotech and pharmaceutical market, primarily serving patients with relapsed and refractory B cell cancers. The company follows a clinical-stage business model, advancing its therapies through rigorous clinical trials to achieve regulatory approval. Revenue generation is anticipated through successful commercialization of its therapies post-approval.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Irvine, United States
Employees: 11
Open positions: None listed
Dealroom signal: 39.1/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Dec 2024	$11M	$44M	The Institute for Follicular Lymphoma Innovation	↗
SERIES AEquity / VC	Oct 2017	$4M	$16M	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

PeproMene Bio website traffic

Latest recorded traffic for PeproMene Bio is 1.6K monthly website visits, up 23.1% over the last three months. PeproMene Bio's team grew 10% over the past year.

Latest monthly visits1.6K 3-month web change+23.1% 1-year team growth+10%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBioMimirAnti-inflammatory, biosynthetic polymers for advanced wound care	Sherbrooke, Canada	Operational	5	—	—
TDThrive Earlier DetectionDeveloping CancerSEEK, a blood-based test for early-stage cancer detection	Cambridge, United States	Acquired
GEGeneoscopyGeneoscopy is developing a screening methodology to noninvasively diagnose colorectal cancer using biomarkers in stool samples	Maryland Heights, United States	Operational
ACAccuri CytometersMedical device company developing cost effective cytometers for laboratories	Ann Arbor, United States	Acquired
TUTreat UDevelopment of targeted nanotechnology-based platforms Biotechnology	Coimbra, Portugal	Operational
AMamcureDeveloping cancer therapeutics	Eggenstein-Leopoldshafen, Germany	Closed
RURubitectionProviding tools for effective skin health management and opportunities for mentorship	Pittsburgh, United States	Operational
XSXenex Disinfection ServicesThe Xenex mission is to save lives and reduce suffering by destroying deadly microorganisms that can cause hospital acquired infections	San Antonio, United States	Operational